What is Maze Therapeutics, Inc. Common Stock's Market Cap?

Maze Therapeutics, Inc. Common Stock's Market Cap is $1.7B, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's Enterprise Value?

Maze Therapeutics, Inc. Common Stock's Enterprise Value is $1.4B, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's EV / EBITDA?

Maze Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's Net Income (TTM)?

Maze Therapeutics, Inc. Common Stock's Net Income (TTM) is -$133.6M, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's EBITDA?

Maze Therapeutics, Inc. Common Stock's EBITDA is -$143.7M, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Maze Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.40, based on as-reported figures from SEC (XBRL) filings.

What is Maze Therapeutics, Inc. Common Stock's Net Debt?

Maze Therapeutics, Inc. Common Stock's Net Debt is -$372.1M, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Maze Therapeutics, Inc. Common Stock

XNAS · usd

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00NHJHS36

31.01▼ 0.94 (-2.94%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value
Trailing P/E: —
Price / Sales: —
EV / Revenue: —
EV / EBITDA

Financial Highlights

Revenue (TTM): —
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin: —
Net Debt

Trading Information

Previous Close: 31.95
Day's Range: 30.54 – 31.86
52-Week Range: 21.95 – 53.68
Volume: 512.9K
Avg Volume: 925.0K

Share Statistics

Shares Outstanding
Employees: 141
Exchange: XNAS
Listed: 2025-01-31

Share count as of August 5, 2026

Maze Therapeutics, Inc. Common Stock (MAZE) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Maze Therapeutics, Inc. Common Stock (MAZE)

What is Maze Therapeutics, Inc. Common Stock's Market Cap?: Maze Therapeutics, Inc. Common Stock's Market Cap is $1.7B, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's Enterprise Value?: Maze Therapeutics, Inc. Common Stock's Enterprise Value is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's EV / EBITDA?: Maze Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's Net Income (TTM)?: Maze Therapeutics, Inc. Common Stock's Net Income (TTM) is -$133.6M, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's EBITDA?: Maze Therapeutics, Inc. Common Stock's EBITDA is -$143.7M, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Maze Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.40, based on as-reported figures from SEC (XBRL) filings.
What is Maze Therapeutics, Inc. Common Stock's Net Debt?: Maze Therapeutics, Inc. Common Stock's Net Debt is -$372.1M, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · MAZEAs-filed SEC (XBRL) data